Kidney conditions: CKD and SGLT2 inhibitors

Indicator

IND322. The percentage of patients on the CKD register and currently treated with an angiotensin receptor blocker (ARB) or an ACE inhibitor (unless these are contraindicated) who are also treated with an SGLT-2 inhibitor if they have:

• no type 2 diabetes and an eGFR 20 ml/min/1.73 m² to 44 ml/min/1.73 m², or
• no type 2 diabetes and an eGFR 45 ml/min/1.73 m² to 59 ml/min/1.73 m² and a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more, or
• type 2 diabetes and a urine ACR 3 mg/mmol or more

Resource impact

The indicator is intended to replace the following current indicator:

IND262: The percentage of patients on the CKD register and currently treated with an ARB or an ACE inhibitor who are also currently treated with an SGLT2 inhibitor if they have either:

• no type 2 diabetes and a urine ACR of 22.6 mg/mmol or more, or
• type 2 diabetes and a urine ACR 3 mg/mmol or more.

Management of chronic kidney disease (CKD) aims to prevent or delay disease progression and the development of complications. SGLT-2 inhibitors can be used as an add on to standard care with ARBs or ACE inhibitors for people with CKD as there is evidence for benefits in terms of CKD progression, cardiovascular events and mortality. Modifiable risks for diabetic ketoacidosis should be addressed for people with type 2 diabetes before starting on an SGLT-2 inhibitor.

It is not anticipated that there will be any additional appointments in primary care as a result of the indicator since the people covered by the criteria in the indicator are already on the CKD register.

Based on the NHSE Drug tariff price for the SGLT-2 inhibitor dapagliflozin, the annual cost of treatment per person with an SGLT-2 inhibitor is estimated at around £182 (excluding VAT). For every 10 additional people per practice who go on to have an SGLT-2 inhibitor in addition to standard care, the additional drug cost is therefore around £1,820.